Marker Therapeutics Inc (MRKR)

[hanscott]

Looks like the Dow is back down again. As to why we were not bouncing with the Dow, probably in part because our chart is broken, to put it kindly, lol. If you look at a weekly chart we were bouncing on support on the 50 week Exponential Moving Average since the start of November and this week crashed through it. Kinda ugly.

I imagine there is some tax-loss selling making things worse. And if the markets bounce back in January I imagine most money will likely flow into high quality names that had a significant correction before it finds its way into MRKR. Or we might snap back like a rubber band in early January, one never knows of course. . .

In the meantime, from Peter's Nov 28 presentation:

What are the key milestones for 2019?

<<Peter Hoang, President and Chief Executive Officer>>

Towards the end of the year, we do expect to have an amended clinical trial protocol at Baylor, which will allow us to actually accelerate the patient enrollment in the current AML study at Baylor. And actually expand that trial to two to four additional centers.

At ASBMT in February, that's the American Society for Blood and Marrow Transplant. We expect to have another data update that will include additional patients in the AML study. And there I think we will have a meaningful number of patients with additional information to update the investor community.

We expect around that time to have our pre-IND meeting for our pivotal Phase 2 study, the seamless pivotal Phase 2 with a filing of the IND no later than the early third quarter. We do expect to have first patient in that seamless Phase 2 before year-end. We expect that to be about 27 multicenter trial that should be able to read out within 18 to 24 months of initiation.

https://markertherapeutics.com/wp-content/uploads/2018/11/Evercore-HealthConX-Transcript.pdf